Posaconazole exposure in critically ill ICU patients: a need for action

[1] Taccone FS(2015)Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes Crit Care 19 7-1222

[2] Van den Abeele AM(2019)Invasive pulmonary aspergillosis Dtsch Med Wochenschr 144 1218-1340

[3] Bulpa P(2022)Pathogenesis of respiratory viral and fungal coinfections Clin Microbiol Rev 35 1339-e162

[4] Misset B(2021)COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges Intensive Care Med 47 e149-e60

[5] Meersseman W(2021)Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance Lancet Infect Dis 21 e1-e38

[6] Cardoso T(2016)Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America Clin Infect Dis 63 e1-509

[7] Matthews H(2018)Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline Clin Microbiol Infect 24 499-222

[8] Rohde H(2021)Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial Lancet 397 218-966

[9] Wichmann D(2004)Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults Br J Clin Pharmacol 57 958-3551

[10] Kluge S(2009)Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob Agents Chemother 53 3543-509

[1] Taccone FS(2015)Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes Crit Care 19 7-1222

[2] Van den Abeele AM(2019)Invasive pulmonary aspergillosis Dtsch Med Wochenschr 144 1218-1340

[3] Bulpa P(2022)Pathogenesis of respiratory viral and fungal coinfections Clin Microbiol Rev 35 1339-e162

[4] Misset B(2021)COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges Intensive Care Med 47 e149-e60

[5] Meersseman W(2021)Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance Lancet Infect Dis 21 e1-e38

[6] Cardoso T(2016)Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America Clin Infect Dis 63 e1-509

[7] Matthews H(2018)Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline Clin Microbiol Infect 24 499-222

[8] Rohde H(2021)Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial Lancet 397 218-966

[9] Wichmann D(2004)Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults Br J Clin Pharmacol 57 958-3551

[10] Kluge S(2009)Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob Agents Chemother 53 3543-509